Drug Profile
Research programme: RNA based immunotherapeutics - Rigontec
Alternative Names: ImOl 200; ImOl 201; Retinoic acid inducible gene I receptor agonists - RigontecLatest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator Rigontec
- Class Oligonucleotides; RNA; Small molecules
- Mechanism of Action DDX58 protein stimulants; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Inflammation; Viral infections
Most Recent Events
- 24 Jul 2023 Preclinical development is ongoing in Germany (Rigontec website, July 2023)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Inflammation in Germany
- 28 Feb 2018 No recent reports of development identified for preclinical development in Cancer in Germany